Hartington Pharmaceutical

What Hartington Pharmaceutical does

Hartington Pharmaceutical is a privately held, Spain-based biopharmaceutical company founded in 1996 that develops and manufactures pharmaceutical preparations derived from natural substances, with a focus on the active ingredient Cyclamen europaeum L. extract. Its core product is Nasodren®, a nasal spray indicated for relief of common cold and acute and chronic rhinosinusitis symptoms, supported by 30 clinical trials across more than 2,000 patients, FDA Type II Drug Master File #20641, European GMP-certified lyophilization manufacturing, and inclusion in the EPOS 2012 European treatment guidelines. The portfolio is being extended into dermatology (Lazolex® topical emollient gel, targeted Q1 2025) and consumer cosmetics (Lazonail® nail care gel and Lazo Be-Feet® foot/elbow moisturizer, targeted Q3 2024), all leveraging the company's natural-substance biotechnology platform.

The company's go-to-market is a hybrid of licensing-out to international pharmaceutical distributors in 40+ countries, direct distribution via subsidiaries in Eastern Europe and CIS markets, and direct-to-consumer e-commerce in Spain. Over 2 million units of Nasodren® have been sold worldwide. The group is family-controlled — founded by Dr. Margaret Mtchedlidze and a group of ENT experts, with Dimitri Mtchedlidze as CEO and Vakhtang Mtchedlidze leading R&D — and is structured around Hartington Business S.L. (parent), Hartington Pharmaceutical S.L. Unipersonal (operating subsidiary), and Hartington Pharma Ltd. (UK regulatory entity). Hartington reinvests 25% of annual revenue into R&D, maintains an Independent Scientific Advisory Committee of leading ENT specialists, and is pursuing additional licensing partnerships to extend its product footprint into new therapeutic areas and geographies.

Name

Hartington Pharmaceutical

Legal name

Hartington Business, S.L.

Website

https://hartington.org

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Hartington Pharmaceutical is a Spain-based, family-owned biopharmaceutical company founded in 1996 that develops natural-substance medicines, led by its core product Nasodren® (a Cyclamen europaeum nasal spray for sinusitis), distributed via licensing partnerships in 40+ countries and direct sales in Spain.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Soap and Cleaning Compound Manufacturing (32561)

SIC

Medicinal Chemicals & Botanical Products (2833), Perfumes, Cosmetics & Other Toilet Preparations (2844)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Dermatology Specialty Pharmaceuticals (HLAIACAL), Dermatology OTC & Skin Health (Acne Treatments, Eczema/Psoriasis OTC, Antifungals, Wart Removal) (CRADAMAF)

Keywords

• Natural pharmaceutical products
• Rhinosinusitis nasal spray
• ENT respiratory medicines
• Dermatology topical gel
• Lyophilized herbal extracts

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Nasodren): Direct sales of pharmaceutical products including Nasodren® nasal spray for rhinosinusitis treatment. Products sold in multiple countries through various distribution channels with over 2 million units sold worldwide.
2. Licensing Out: Licensing agreements with pharmaceutical companies worldwide. Partners receive full support during registration process, marketing advice, promotional materials, and scientific evidence. Products available for licensing include Lazonail® and future products.
3. Cosmetic Products: Sales of cosmetic products including Lazonail® nail care and Lazo Be-Feet® moisturizing product. Lazonail available for licensing out.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Hartington Pharmaceutical develops, manufactures, and licenses pharmaceutical and cosmetic products based on natural substances, with Nasodren® (a Cyclamen europaeum L. extract nasal spray for rhinosinusitis) as its flagship product. The company also offers Lazolex® (a silicone-based topical emollient gel for dermatitis), Lazonail® (a walnut extract nail care gel), and Lazo Be-Feet® (a moisturizing cosmetic for feet and elbows), distributing them worldwide via licensing partners in 40+ countries and direct e-commerce in Spain.

Product overview

Hartington Pharmaceutical offers a portfolio of pharmaceutical and cosmetic products based on natural substances, comprising four distinct offerings: Nasodren® is a core respiratory pharmaceutical (nasal spray) for sinusitis treatment; Lazolex® is a core dermatological pharmaceutical (topical emollient gel) for skin inflammation relief; Lazonail® is a cosmetic nail care gel for nail strengthening; and Lazo Be-Feet® is a cosmetic skin care product for feet and elbow moisturization. The products are unified by the company's focus on natural-origin ingredients combined with advanced pharmaceutical technology, with Nasodren® being the most established product with over 2 million units sold worldwide.

Differentiator

Problem solved

Functional benefit

Brands

• Nasodren®: Nasal spray indicated to relieve common cold and sinusitis symptoms. Active ingredient is Cyclamen europaeum extract, 100% natural. Dual mechanism of action leads to fast drainage of nasal mucosa and paranasal sinuses.
• Lazonail®
• Lazo Be-Feet®
• Lazolex®

Products and services

• Nasodren® Nasal spray indicated to relieve common cold and sinusitis symptoms, with Cyclamen europaeum extract (100% natural) as its active ingredient. Features a unique dual mechanism of action leading to fast drainage of nasal mucosa and paranasal sinuses, providing an effective, safe natural-based alternative to antibiotics and avoiding surgical intervention. Over 2 million units sold worldwide.
• Lazolex® Topical emollient gel for dermatological use, manufactured from three different silicones with well-known emollient properties. Creates a mechanical barrier providing an optimal environment for skin inflammation management, indicated to relieve itching, stinging, burning, and dry skin in cases of dermatitis. Demonstrated penetrability in the epidermis with low penetrability in the dermis for systemic therapeutic safety.
• Lazonail® Innovative nail care gel created with walnut extract and vital minerals like calcium and zinc, designed for rapid absorption to improve nail strength and health within 7 days. Demonstrated 10% increase in nail hardness after first application.
• Lazo Be-Feet® Premium cosmetic product for moisturizing and repairing feet and elbows, formulated with a unique blend of hydrating and repairing ingredients to combat dryness, roughness, and cracking. 84% of volunteers experienced noticeable improvement within 7 days.

Quantifiable outcome

• Over 2 million units of Nasodren® sold worldwide
• +5 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• International Pharmaceutical DistributorscoreChannel Partner/ Reseller/ DistributorHartington has expanded its distribution network forging agreements with pharmaceutical companies worldwide to offer effective and safe natural-based products. Partners receive full support during registration process, marketing advice, wide range of promotional materials and scientific evidences. Countries include Russia, Germany, Spain, Poland, Greece, Romania, Bulgaria, Netherlands, Belgium, France, Switzerland, Sweden, Australia, Saudi Arabia, Serbia, Finland, Turkmenistan and others.
• Biotech and Clinical Research CompaniescoreStrategic or Co-development PartnerCollaboration agreements with biotech and clinical research companies for the discovery, development and distribution of new treatments. These strategic partnerships strengthen Hartington's position at the vanguard of the fight against disease.
• International Pharmaceutical Companies of RenowncoreStrategic or Co-development PartnerCollaboration with pharmaceutical companies of international renown for discovery, development and distribution of new treatments. Hartington also licensed Fluirespira Forte® from Zambon Group in 2006 for Western European market.
• Worldwide Network of Collaborating ExpertscoreStrategic or Co-development PartnerCompany maintains a worldwide network of collaborating experts together with latest modern technologies for discovering new products and subsequently producing them. Independent Scientific Advisory Committee formed by leading ENT specialists supports ongoing research.
• Médicos del Mundo (Medicos del Mundo)minorOthersSocial support partnership with Médicos del Mundo organization for humanitarian healthcare initiatives.
• IveriapharmacoreStrategic or Co-development PartnerFounded in Georgia in 1998 to enable clinical trials for Sinuforte® (later Nasodren®). Hartington Pharma Ltd established in 2007 for manufacturing of Nasodren®.
• Zambon GroupminorChannel Partner/ Reseller/ DistributorLicensed Fluirespira Forte® from Zambon Group in 2006 for Western European pharmaceutical market entry.

Scale indicators6 records

Recent moves14 records

Expansion highlights5 records

Direct peers

• Cassella-med GmbH & Co. KG (Klosterfrau): German natural-medicine and OTC specialist with a portfolio of plant-based respiratory, dermatology, and consumer health brands sold across Europe. Comparable in its natural-source formulation strategy and pharmacy-channel distribution model.
• Zambon Group: Italian pharmaceutical company with a respiratory franchise and an active licensing business. Hartington has an existing commercial relationship with Zambon (Fluirespira Forte® in-licensing), making it a closely linked comparable in the European respiratory market.
• Boiron: French global leader in homeopathic and natural-source medicines, distributed primarily via pharmacies across 50+ countries. Comparable to Hartington in its reliance on natural-origin products, pharmacy-channel distribution, and broad international licensing footprint.
• Schwabe Group (Dr. Willmar Schwabe): German-based global leader in phytopharmaceuticals, specializing in clinically validated botanical medicines. Comparable to Hartington in its focus on natural-source active ingredients, strong clinical evidence generation, and international licensing model.
• Bionorica SE: German family-owned phytopharmaceutical company developing and licensing plant-based prescription and OTC products, with a strong respiratory/sinusitis portfolio (e.g., Sinupret). Highly comparable to Hartington's natural-substance, licensing-out business model.
• Heel GmbH: German biotherapeutics and natural-medicine company with a portfolio spanning respiratory, dermatology, and OTC categories. Comparable to Hartington in its natural-source, evidence-based positioning and multi-product international licensing model.

Broad incumbents

• Perrigo Company plc: Global consumer self-care company with OTC and dermatology/skincare brands distributed through pharmacy channels. Comparable as a larger incumbent in the OTC respiratory and dermatology categories where Hartington competes.
• Stada Arzneimittel AG: European generics and consumer healthcare company with a broad OTC/respiratory portfolio across 30+ markets. Comparable as a larger incumbent operating in the same specialty and OTC respiratory/dermatology categories where Hartington licenses Nasodren® and Lazolex®.
• Meda Pharma (part of Viatris): European specialty pharma (now under Viatris) with strong respiratory and dermatology OTC presence and extensive European licensing/distribution. Comparable incumbent in the same therapy areas and geographies as Hartington's Nasodren® and Lazolex®.

Emerging players

• Glenmark Pharmaceuticals: India-headquartered specialty pharma with a meaningful respiratory franchise and international licensing activity. Comparable as an emerging player with overlapping respiratory indications and a cross-border out-licensing model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/HartingtonPharma
• Facebookfacebook.com/hartington.pharmaceutical
• LinkedInlinkedin.com/company/hartington-pharmaceutical

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hartington Pharmaceutical